drugset / Trial / NCT00444574

Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

NCT00444574

Phase 3 Completed 282 enrolled Noven Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA® in pediatric subjects diagnosed with ADHD.

Timeline

Start
2004-09
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylphenidate Small molecule 2.7 mg Other
Comparator Methylphenidate Small molecule 10 mg Other
Comparator Methylphenidate Small molecule 15 mg Other
Comparator Methylphenidate Small molecule 18 mg Other
Comparator Methylphenidate Small molecule 20 mg Other
Comparator Methylphenidate Small molecule 27 mg Other
Comparator Methylphenidate Small molecule 30 mg Other
Comparator Methylphenidate Small molecule 36 mg Other
Comparator Methylphenidate Small molecule 41.3 mg Other
Comparator Methylphenidate Small molecule 54 mg Other
Comparator Methylphenidate Small molecule 55 mg Other
Comparator Methylphenidate Small molecule 82.5 mg Other